Patents by Inventor Roger Gingrich

Roger Gingrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized antibodies against CD3
    Patent number: 7381803
    Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: June 3, 2008
    Assignees: PDL BioPharma, Inc., Iowa Immunotherapy Investigators
    Inventors: George Weiner, Roger Gingrich, Brian K. Link, J. Yun Tso
  • HUMANIZED ANTIBODIES AGAINST CD3
    Publication number: 20080025975
    Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
    Type: Application
    Filed: March 26, 2007
    Publication date: January 31, 2008
    Applicants: Protein Design Labs, Inc., Iowa Immunotherapy Investigators
    Inventors: George Weiner, Roger Gingrich, Brian Link, J. Tso
  • Humanized antibodies against CD3
    Publication number: 20040052783
    Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
    Type: Application
    Filed: May 9, 2003
    Publication date: March 18, 2004
    Applicants: Protein Design Labs, Inc., Iowa Immunotherapy Investigators
    Inventors: George Weiner, Roger Gingrich, Brian K. Link, J. Yun Tso
  • Bispecific antibody effective to treat B-cell lymphoma and cell line
    Patent number: 6129914
    Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: October 10, 2000
    Assignee: Protein Design Labs, Inc.
    Inventors: George Weiner, Roger Gingrich, Brian K. Link, J. Yun Tso